Business Description
Scilex Holding Co
NAICS : 325411
SIC : 2834
ISIN : US80880W1062
Description
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.06 | |||||
| Equity-to-Asset | -2.05 | |||||
| Debt-to-Equity | -0.5 | |||||
| Debt-to-EBITDA | -0.95 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | -12.82 | |||||
| Beneish M-Score | -7.97 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 26.6 | |||||
| 3-Year EBITDA Growth Rate | -53.6 | |||||
| 3-Year EPS without NRI Growth Rate | -52 | |||||
| 3-Year FCF Growth Rate | 12.1 | |||||
| 3-Year Book Growth Rate | -17.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 29.75 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 22.73 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.89 | |||||
| 9-Day RSI | 31.85 | |||||
| 14-Day RSI | 34.51 | |||||
| 3-1 Month Momentum % | -35.65 | |||||
| 6-1 Month Momentum % | -50.34 | |||||
| 12-1 Month Momentum % | -35.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.2 | |||||
| Quick Ratio | 0.19 | |||||
| Cash Ratio | 0.03 | |||||
| Days Inventory | 80.61 | |||||
| Days Sales Outstanding | 210.12 | |||||
| Days Payable | 763.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 9.1 | |||||
| Shareholder Yield % | -177.42 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.24 | |||||
| Operating Margin % | -195.02 | |||||
| Net Margin % | -233.88 | |||||
| FCF Margin % | 23.43 | |||||
| ROA % | -117.92 | |||||
| ROIC % | -70.12 | |||||
| 3-Year ROIIC % | -92.63 | |||||
| ROC (Joel Greenblatt) % | -3174.85 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.14 | |||||
| Price-to-Free-Cash-Flow | 5.42 | |||||
| Price-to-Operating-Cash-Flow | 5.25 | |||||
| EV-to-EBIT | -1.45 | |||||
| EV-to-Forward-EBIT | -5.87 | |||||
| EV-to-EBITDA | -1.5 | |||||
| EV-to-Revenue | 3.33 | |||||
| EV-to-Forward-Revenue | 2.27 | |||||
| EV-to-FCF | 14.19 | |||||
| Earnings Yield (Greenblatt) % | -68.97 | |||||
| FCF Yield % | 17.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SCLX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Scilex Holding Co Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 50.833 | ||
| EPS (TTM) ($) | -1.43 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 141.44 | ||
| 14-Day RSI | 34.51 | ||
| 14-Day ATR ($) | 0.087124 | ||
| 20-Day SMA ($) | 0.603475 | ||
| 12-1 Month Momentum % | -35.65 | ||
| 52-Week Range ($) | 0.4559 - 2.63 | ||
| Shares Outstanding (Mil) | 133.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Scilex Holding Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Scilex Holding Co Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Scilex Holding Co Frequently Asked Questions
What is Scilex Holding Co(SCLX)'s stock price today?
The current price of SCLX is $0.51. The 52 week high of SCLX is $2.63 and 52 week low is $0.46.
When is next earnings date of Scilex Holding Co(SCLX)?
The next earnings date of Scilex Holding Co(SCLX) is 2024-12-19 Est..
Does Scilex Holding Co(SCLX) pay dividends? If so, how much?
Scilex Holding Co(SCLX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers